Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2500 participants
OBSERVATIONAL
2024-06-26
2028-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Colorectal Cancer Screening French Organizations for the Follow-up After Colonoscopy
NCT03383367
Sensitivity of Fecal Immunochemical Test (FIT) for Colorectal Cancer (CRC) Screening
NCT05163236
Faecal Microbiota Characterization in Lynch Syndrome (LS) Patients With or Without Colorectal Neoplasia
NCT04791644
The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer
NCT01688232
Personalizing Colorectal Cancer Medicine (ImmuCol2)
NCT02274753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is an ancillary study of "Le French Gut" study (NCT05758961), a national contribution aiming to collect 100,000 faecal samples and associated nutritional and clinical data. Here, the aim is to identify microbiota profiles associated with the presence of adenomas, advanced adenomas and colorectal cancer (CRC), which would make it possible to recommend follow-up colonoscopies in a more targeted way than the current screening method. The study involves 2,500 patients aged between 50 and 75 who were due to undergo colonoscopy as part of their routine care. Patients recruited in this way will take part in the main "Le French Gut" study, will undergo a colonoscopy as part of their routine care and will complete 2 specific questionnaires relating to their personal and family history as well as their dietary habits in order to assess the risk factors for colorectal cancer as accurately as possible. The FIT test will be carried out as part of routine care with home sampling at the same time as stool sampling using the stool collection kit from the "French Gut" study (same stool sample).
Metagenomic fecal analysis will be coupled with a federated artificial intelligence tool incorporating data collected as part of the French Gut study and specific parameters describing the level of CRC risk. The diagnostic value of the signatures will be compared with that of the FIT test currently used for CRC screening.The ultimate aim is to develop more accurate, non-invasive ways of predicting CRC risk, based on a non-invasive fecal swab that can be taken at home.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Requiring colonoscopy
* Able to provide a faecal sample and to perform a FIT test prior to colonoscopy
* Without known inflammatory bowel disease (chronic inflammatory bowel disease (IBD), chronic ulcerative colitis (CUC) and Crohn's disease (CD))
* No medical condition that, in the opinion of the investigator, should preclude inclusion in the study
* Not having participated in any other clinical research study in which an investigational drug has been administered within 60 days prior to and including the date of informed consent or is likely to be administered during the period of colonoscopy
* Participation agreement signed electronically
Exclusion Criteria
* Persons subject to a protective measure, in particular guardianship or trusteeship, or unable to express their consent (declarative);
* Persons who have had a colectomy (declaratory);
* Person with a digestive stoma (declaration);
* Person who did not sign the consent form;
* Person who did not answer the entry questionnaire;
* Person who did not send a compliant stool sample;
* Antibiotics taken in the 3 months prior to inclusion (self-report);
* Person aged under 50 or over 75.
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ROBERT BENAMOUZIG, Pr
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Avicenne, Centre de Recherche sur Volontaire
Bobigny, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01941-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.